Respiratory distress syndrome at birth is a risk factor for hospitalization for lower respiratory tract infections in infancy

Pediatric Infectious Disease Journal

Volumn 31, Issue 12, 2012, Pages 1245-1251

  Szabo, Shelagh M ^a   Gooch, Katherine L ^b   Korol, Ellen E ^a   Bradt, Pamela ^b   Vo, Pamela ^b   Levy, Adrian R ^a  

^a ICON PLC   (United Kingdom)

^b Adzoe Inc   (United States)

Author keywords

Hospitalization; Infant; Lower respiratory tract infection; Respiratory distress syndrome; Respiratory syncytial virus

Indexed keywords

ARTICLE; BACTEREMIA; BRAIN HEMORRHAGE; CHILD HOSPITALIZATION; CHILDBIRTH; CHRONIC BRONCHITIS; COHORT ANALYSIS; CONGENITAL HEART DISEASE; DIAPHRAGM DISEASE; DISEASE ASSOCIATION; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORBIDITY; NEONATAL RESPIRATORY DISTRESS SYNDROME; POPULATION RESEARCH; PREMATURITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; WHEEZING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; QUEBEC; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84870899127     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182737349     Document Type: Article

References (47)

1. Kamath BD, Macguire ER, McClure EM, et al. Neonatal mortality from respiratory distress syndrome: lessons for low-resource countries. Pediatrics. 2011;127:1139-1146.
2. Canadian Institute for Health Information, Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada. Report; 2007. Available by request from: chronic.publications.chronique@phac-aspc.gc.ca.
3. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child. 1959;97:517-523.
4. Underwood MA, Danielsen B, Gilbert WM. Cost, causes and rates of rehospitalization of preterm infants. J Perinatol. 2007;27:614-619.
5. Resch B, Paes B. Are late preterm infants as susceptible to RSV infection as full term infants? Early Hum Dev. 2011;87(suppl 1):S47-S49.
6. Lanari M, Silvestri M, Rossi GA. Respiratory syncytial virus risk factors in late preterm infants. J Matern Fetal Neonatal Med. 2009;22(suppl 3): 102-107.
7. Groothuis JR, Fryzek J P, Makari D, et al. Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998-2008. Clin Epidemiol. 2011;3:245-250.
8. Koivisto M, Marttila R, Saarela T, et al. Wheezing illness and re-hospitalization in the first two years of life after neonatal respiratory distress syndrome. J Pediatr. 2005;147:486-492.
9. Regie de l'assurance Maladie du Quebec. Statistiques Annuelles 1993. Québec City, Québec, Canada: RAMQ; 1994.
10. Bérard A, Lacasse A. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. Can J Clin Pharmacol. 2009;16:e360-e369.
11. Levy AR, Tamblyn RM, Fitchett D, et al. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol. 1999;15:1277-1282.
12. Kapur V, Basu K. Drug coverage in Canada: who is at risk? Health Policy. 2005;71:181-193.
13. Regie de l'assurance Maladie du Quebec. Data and statistics. 2010. Available at: http://www.ramq.gouv.qc.ca/en/statistiques/index.shtml. Accessed April 6, 2010.
14. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137:865-870.
15. Fixler DE. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatr Cardiol. 1996;17:163-168.
16. Te Pas AB, Lopriore E, Engbers MJ, et al. Early respiratory management of respiratory distress syndrome in very preterm infants and bronchopulmonary dysplasia: a case-control study. PLoS ONE. 2007;2:e192.
17. Van Marter LJ, Dammann O, Allred EN, et al.; Developmental Epidemiology Network Investigators. Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. J Pediatr. 2002;140:171-176.
18. Patrianakos-Hoobler AI, Marks JD, Msall ME, et al. Safety and efficacy of inhaled nitric oxide treatment for premature infants with respiratory distress syndrome: follow-up evaluation at early school age. Acta Paediatr. 2011;100:524-528.
19. Korhonen P, Koivisto AM, Ikonen S, et al. Very low birthweight, bronchopulmonary dysplasia and health in early childhood. Acta Paediatr. 1999;88:1385-1391.
20. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
21. Doyle LW, Anderson PJ. Long-term outcomes of bronchopulmonary dysplasia. Semin Fetal Neonatal Med. 2009;14:391-395.
22. Feltes TF, Cabalka AK, Meissner HC, et al.; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540.
23. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res. 1999;46:641-643.
24. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282:1440-1446.
25. Martinez FD, Morgan WJ, Wright AL, et al. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med. 1988;319:1112-1117.
26. Abdel-Latif ME, Osborn DA. Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev. 2011:CD008309.
27. Finer NN, Carlo WA, Walsh MC, et al.; SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362:1970-1979.
28. Kattwinkel J, Robinson M, Bloom BT, et al. Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol. 2004;24:360-365.
29. Szabo SM, Gooch KL, Wijaya H, et al. RSV hospitalization in infancy is associated with an increased risk of respiratory morbidity: a population-based study. Paper presented at: Excellence in Pediatrics Congress; November 30-December 3, 2011; Istanbul, Turkey. Abstract.
30. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118:1774-1793.
31. Kaneko M, Watanabe J, Kuwahara M, et al. Impact of respiratory syncytial virus infection as a cause of lower respiratory tract infection in children younger than 3 years of age in Japan. J Infect. 2002;44:240-243.
32. Lanari M, Giovannini M, Giuffré L, et al.; Investigators R.A.DA.R. Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol. 2002;33:458-465.
33. Flaherman V, Li S, Ragins A, et al. Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: a retrospective cohort study. Clin Ther. 2010;32:2220-2229.
34. Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Sudbury, MA: Jones and Bartlett; 2004.
35. Palmer L, Hall CB, Katkin J P, et al. Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants. Curr Med Res Opin. 2011;27:403-412.
36. Liem JJ, Huq SI, Ekuma O, et al. Transient tachypnea of the newborn may be an early clinical manifestation of wheezing symptoms. J Pediatr. 2007;151:29-33.
37. Rosychuk RJ, Klassen T P, Voaklander DC, et al. Presentations of infants to emergency departments in Alberta, Canada, for bronchiolitis: a large population-based study. Pediatr Emerg Care. 2011;27:189-195.
38. Rosychuk RJ, Voaklander DC, Klassen T P, et al. A population-based study of emergency department presentations for asthma in regions of Alberta. CJEM. 2010;12:339-346.
39. Holman RC, Shay DK, Curns AT, et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J. 2003;22:483-489.
40. Rowe BH, Voaklander DC, Wang D, et al. Asthma presentations by adults to emergency departments in Alberta, Canada: a large population-based study. Chest. 2009;135:57-65.
41. Delea TE, Hagiwara M, Dalal AA, et al. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. Curr Med Res Opin. 2009;25:1-13.
42. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130:397-403.
43. Vilain A, Otis S, Forget A, et al. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol Drug Saf. 2008;17:345-353.
44. Blais L, Lemière C, Menzies D, et al. Validity of asthma diagnoses recorded in the Medical Services database of Quebec. Pharmacoepidemiol Drug Saf. 2006;15:245-252.
45. McKnight J, Scott A, Menzies D, et al. A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J Clin Epidemiol. 2005;58:206-208.
46. Agency for Healthcare Research and Quality (AHRQ). Quality indicator development. Available at: http://www.qualityindicators.ahrq.gov/FAQs-Support/ FAQ-QI.aspx. Accessed February 28, 2011.
47. Food and Drug Administration. Synagis(R) (Palivizumab) for intramuscular administration; 1999.